UroGen Pharma Ltd. (URGN)
43.62
-1.88
(-4.13%)
USD |
NASDAQ |
Aug 28, 16:00
43.61
-0.01
(-0.02%)
After-Hours: 20:00
UroGen Pharma Gross Profit Margin (Quarterly) : 90.93% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 90.93% |
| March 31, 2026 | 91.88% |
| December 31, 2025 | 91.31% |
| September 30, 2025 | 88.07% |
| June 30, 2025 | 85.34% |
| March 31, 2025 | 88.50% |
| December 31, 2024 | 89.94% |
| September 30, 2024 | 90.27% |
| June 30, 2024 | 89.80% |
| March 31, 2024 | 90.80% |
| December 31, 2023 | 90.28% |
| September 30, 2023 | 88.65% |
| June 30, 2023 | 88.44% |
| March 31, 2023 | 86.83% |
| December 31, 2022 | 87.49% |
| September 30, 2022 | 87.45% |
| June 30, 2022 | 88.88% |
| March 31, 2022 | 88.76% |
| Date | Value |
|---|---|
| December 31, 2021 | 90.18% |
| September 30, 2021 | 89.04% |
| June 30, 2021 | 89.05% |
| March 31, 2021 | 88.02% |
| December 31, 2020 | 84.09% |
| September 30, 2020 | 76.68% |
| June 30, 2020 | -40.59% |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | 0.00% |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | -272.8% |
| June 30, 2018 | 12.64% |
| March 31, 2018 | 10.60% |
| December 31, 2017 | 12.23% |
| September 30, 2017 | 96.22% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Insmed, Inc. | 83.71% |
| Xencor, Inc. | 95.24% |
| MeiraGTx Holdings Plc | 96.89% |
| IDEAYA Biosciences, Inc. | 87.21% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -44.36% |
| Return on Invested Capital | -232.7% |
| Profit Margin (Quarterly) | -19.81% |
| Operating Margin (Quarterly) | 0.15% |
| Return on Net Operating Assets | -145.6% |